SEAGEN INC.
BOTHELL, WA

Seattle Genetics, Inc. is a prominent oncology biotechnology company headquartered in Bothell, Washington (File Number F11000000297), incorporated on January 24, 2011. It specializes in developing and commercializing cutting-edge antibody-based therapies for cancer treatment through its proprietary antibody-drug conjugate (ADC) technology. The company's flagship product, ADCETRIS® (brentuximab vedotin), is the first commercially available ADC approved for use in 70 countries. It treats relapsed classical Hodgkin lymphoma and systemic anaplastic large cell lymphoma, along with two additional indications in the U.S. Leading its diverse pipeline of ADCs aimed at various cancers are collaborations with prominent pharmaceutical companies such as Astellas Pharma Inc., Genentech (a member of the Roche Group), AbbVie, GlaxoSmithKline, and Pfizer. These partnerships have generated over $375 million for Seattle Genetics through strategic licenses. Seattle Genetics is committed to scientific innovation, maintaining integrity, teamwork, and rigorous research practices while nurturing an entrepreneurial spirit that drives breakthrough therapeutics. Under the leadership of notable executives including John A. Orwin (CEO since June 2013 prior to joining Relypsa), Alpna Seth (COO at its board as of July 2017 after serving at Biogen, Inc.), and key figures such as Frances Sewell, Shehzad Siddiqui, and Susan Grant, the company continually progresses in advancing oncology care. The organization fosters a culture dedicated to excellence, fostering growth through innovation and strategic alignments in its field. Its offices are conveniently located for clients at 21823 30th Drive SE, Bothell, WA 98021, with contact numbers readily available (425-527-4000; among others). The last public record change was on October 9, 2020, involving a name amendment to 'SEATTLE GENETICS INC.' For more information, visit the company’s official website at [seattlegenetics.com](http://seattlegenetics.com).